Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer

Genetic analysis is now routine in metastatic non–small-cell lung cancer (NSCLC) to identify somatic sensitizing mutations in EGFR, typically L858R and exon 19 deletion (Ex19del). Patients with these genotypes are treated with first- or second-generation epidermal growth factor receptor tyrosine…

http://ift.tt/2APVRFj